Integra LifeSciences Holdings Corporation 2025-2026 Proxy Voting Records

Description as filed by funds: To elect eight directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified: Stuart M. Essig

Integra LifeSciences Holdings Corporation’s own tally for this item (“Elect Director: Stuart M. Essig, Ph.D.”): 68,172,670 for, 1,113,688 against, per its Form 8-K filed May 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final results of the matters submitted to a vote of stockholders at the Annual Meeting are as follows: Item No. 1: All of the nominees for director of the Board of Directors (the "Board") of the Company were elected to serve until the Company's 2027 Annual Meeting of Stockholders and until thei…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 30,612,168 for, 139,021 against, 20,489 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: To elect eight directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified: Jeffrey A. Graves

Integra LifeSciences Holdings Corporation’s own tally for this item (“Elect Director: Jeffrey A. Graves, Ph.D.”): 65,841,917 for, 3,442,844 against, per its Form 8-K filed May 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final results of the matters submitted to a vote of stockholders at the Annual Meeting are as follows: Item No. 1: All of the nominees for director of the Board of Directors (the "Board") of the Company were elected to serve until the Company's 2027 Annual Meeting of Stockholders and until thei…”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 30,700,521 for, 51,827 against, 19,330 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: To elect eight directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified: Barbara B. Hill

Integra LifeSciences Holdings Corporation’s own tally for this item (“Elect Director: Barbara B. Hill”): 62,241,203 for, 7,042,475 against, per its Form 8-K filed May 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final results of the matters submitted to a vote of stockholders at the Annual Meeting are as follows: Item No. 1: All of the nominees for director of the Board of Directors (the "Board") of the Company were elected to serve until the Company's 2027 Annual Meeting of Stockholders and until thei…”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 29,367,021 for, 1,384,168 against, 20,489 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: To elect eight directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified: Renee W. Lo

Integra LifeSciences Holdings Corporation’s own tally for this item (“Elect Director: Renee W. Lo”): 68,619,639 for, 664,390 against, per its Form 8-K filed May 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final results of the matters submitted to a vote of stockholders at the Annual Meeting are as follows: Item No. 1: All of the nominees for director of the Board of Directors (the "Board") of the Company were elected to serve until the Company's 2027 Annual Meeting of Stockholders and until thei…”
Support: 99.0% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 30,752,977 for, 28,212 against, 20,489 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: To elect eight directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified: Christian S. Schade

Integra LifeSciences Holdings Corporation’s own tally for this item (“Elect Director: Christian S. Schade”): 68,247,357 for, 1,037,010 against, per its Form 8-K filed May 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final results of the matters submitted to a vote of stockholders at the Annual Meeting are as follows: Item No. 1: All of the nominees for director of the Board of Directors (the "Board") of the Company were elected to serve until the Company's 2027 Annual Meeting of Stockholders and until thei…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 30,752,919 for, 28,270 against, 20,489 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: To elect eight directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified: Keith Bradley

Integra LifeSciences Holdings Corporation’s own tally for this item (“Elect Director: Keith Bradley, Ph.D.”): 64,904,372 for, 4,378,288 against, per its Form 8-K filed May 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final results of the matters submitted to a vote of stockholders at the Annual Meeting are as follows: Item No. 1: All of the nominees for director of the Board of Directors (the "Board") of the Company were elected to serve until the Company's 2027 Annual Meeting of Stockholders and until thei…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 30,505,945 for, 185,244 against, 20,489 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: To elect eight directors of the Company to serve until the next annual meeting of stockholders and until their successors are duly elected and qualified: Shaundra D. Clay

Integra LifeSciences Holdings Corporation’s own tally for this item (“Elect Director: Shaundra D. Clay”): 68,996,420 for, 286,939 against, per its Form 8-K filed May 8, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The final results of the matters submitted to a vote of stockholders at the Annual Meeting are as follows: Item No. 1: All of the nominees for director of the Board of Directors (the "Board") of the Company were elected to serve until the Company's 2027 Annual Meeting of Stockholders and until thei…”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 30,662,978 for, 28,211 against, 20,489 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.

Description as filed by funds: ELECTION OF DIRECTOR TO SERVE UNTIL THE NEXT ANNUAL MEETING OF STOCKHOLDERS AND UNTIL THEIR SUCCESSORS ARE DULY ELECTED AND QUALIFIED: MOJDEH POUL

The 18 asset managers below reported 3,537,685 for, 19,511 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Description as filed by funds: To approve Amendment No. 3 to the Integra LifeSciences Holdings Corporation Fifth Amended and Restated 2003 Equity Incentive Plan.

The 73 asset managers below reported 30,648,918 for, 95,208 against, 19,330 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.

Description as filed by funds: To approve, on a non-binding advisory basis, the compensation of our named executive officers.

Integra LifeSciences Holdings Corporation’s own tally for this item (“3. On an advisory, non-binding basis, the compensation of the Company's named executive officers”): 68,472,769 for, 732,580 against — passed, per its Form 8-K filed May 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Item No. 3: The stockholders approved, on an advisory, non-binding basis, the compensation of the Company's named executive officers, by the votes set forth below.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 72 managers: 30,550,606 for, 131,742 against, 81,330 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 201 managers: 35,433,545 for, 542,550 against. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year 2026.

Integra LifeSciences Holdings Corporation’s own tally for this item (“2. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the 2026 fiscal year”): 72,313,820 for, 863,179 against — passed, per its Form 8-K filed May 8, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Item No. 2: The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the 2026 fiscal year, by the votes set forth below.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 72 asset managers below reported 30,725,459 for, 56,889 against, 19,330 abstained.

Showing the 25 largest of 72 asset managers. See all 72 in the interactive database.